Letrozole in Patients With Ovarian Tumors

This study has been terminated.

(Terminated due to slow patient accrual.)

Sponsor:

Information provided by (Responsible Party):

M.D. Anderson Cancer Center

ClinicalTrials.gov Identifier:

NCT00505661

First received: July 19, 2007

Last updated: April 16, 2012

Last verified: April 2012

Results First Received: September 28, 2010

Study Type:	Interventional
Study Design:	Allocation: Non-Randomized; Endpoint Classification: Safety/Efficacy Study; Intervention Model: Single Group Assignment; Masking: Open Label; Primary Purpose: Treatment
Conditions:	Ovarian Cancer Fallopian Tube Cancer Peritoneal Cancer
Intervention:	Drug: Letrozole

Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Recruitment Period: 09/24/03 through 01/30/08. All participants recruited at UT MD Anderson Cancer Center.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Study terminated early due to slow patient accrual.

Reporting Groups

	Description
Letrozole	2.5 mg by mouth (PO) daily

Participant Flow: Overall Study

Baseline Characteristics

Reporting Groups

	Description
Letrozole	2.5 mg by mouth (PO) daily

Baseline Measures

	Letrozole
Number of Participants [units: participants]	16
Age [units: years] Median ( Full Range )	54 ( 43 to 77 )
Gender [units: participants]
Female	16
Male	0
Region of Enrollment [units: participants]
United States	16

Outcome Measures

1. Primary:

Objective Response Rate Following Treatment With Letrozole [ Time Frame: 2 month intervals for first 2 years ]

Show Outcome Measure 1

Serious Adverse Events

Other Adverse Events

More Information